Inhibrx Biosciences Inc (Nasdaq:INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, announced on Tuesday updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 (DR5) agonist, in combination with irinotecan and temozolomide (IRI/TMZ) in patients with relapsed or refractory Ewing sarcoma.
The data will be presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting.
As of the data cutoff on 18 September, 60 patients (including 9 adolescent patients) were enrolled and treated with ozekibart plus IRI/TMZ, with 22 patients remaining on active treatment. Among the 51 response-evaluable patients, the combination demonstrated an overall response rate (ORR) of 62.7%, comprising 2 complete responses (CRs) and 30 partial responses (PRs). A total of 84.3% of response-evaluable patients (43/51) experienced measurable reduction in tumour size from baseline. An additional 12 patients achieved stable disease (SD), resulting in a Disease Control Rate (DCR) of 86.3%.
The median progression free survival (mPFS) was 6.0 months. Durable clinical benefit exceeding 6 months was observed in 18 patients (1 CR, 1 SD, 16 PRs), including 1 patient maintaining an ongoing PR for more than 2 years. At the cutoff date, 14 response-evaluable patients remained progression-free, including 2 patients with a PFS duration exceeding 12 months.
According to the company, these data represent a meaningful improvement over historical benchmarks, such as irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma, which typically yield an ORR of approximately 15% to 30% and mPFS of around 3 to 4 months.
Inhibrx said that the combination continued to demonstrate an acceptable and manageable safety profile consistent with the known cytotoxic toxicities of IRI/TMZ and DR5 agonism, with no evidence of unexpected cumulative hepatotoxicity.
The FDA has accepted for filing the biologics license application for the potential approval of ozekibart in conventional chondrosarcoma.
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Eisai launches subcutaneous Leqembi Pen in Japan for early Alzheimer's disease
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme